AC
ITCI

Avestar Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Avestar Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,600
Closed -$450K – 493
2021
Q4 		$450K Sell
8,600
-807
-9% -$33.9K 0.06% 280
2021
Q3 		$351K Sell
9,407
-16,690
-64% -$580K 0.04% 312
2021
Q2 		$1.06M Buy
26,097
+4,774
+22% +$176K 0.14% 176
2021
Q1 		$730K Buy
+21,323
New +$740K 0.16% 130

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Avestar Capital's ITCI Position: Q1 2022 in Review

Avestar Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2022, closing a stake of 8,600 shares — an estimated $450K sold.

Avestar Capital first reported a position in ITCI in Q1 2021 and held it in 4 quarters. The position peaked at $1.06M in Q2 2021. 241 funds tracked by Wall St. Rank hold ITCI as of Q1 2022.

  • Avestar Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2022 after selling out during the quarter.
  • Avestar Capital sold 8,600 Intra-Cellular Therapies Inc. shares in Q1 2022, an estimated $450K.
  • Avestar Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2021 and held it in 4 quarters.
  • Avestar Capital's Intra-Cellular Therapies Inc. position peaked at $1.06M in Q2 2021.
  • 241 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2022.

Based on Avestar Capital's 13F filing for Q1 2022, filed 26 Apr 2022.